AtriCure has announced that Scott Drake, chief executive officer of Spectranetics has been elected as director. Donald C Harrison, one of the founders of AtriCure, has also informed the board of directors of his plans to retire at the 2013 Annual Meeting in May 2014, following an orderly transition and after almost 20 years of service with the company.
Drake is president and chief executive officer of Spectranetics, developer of minimally invasive procedures within the cardiovascular system. Since joining Spectranetics in August 2011, Drake has led it through significant growth. Spectranetics reported US$140.3 million in revenue in 2012.
Prior to joining Spectranetics, Drake was senior vice president, Operations of DaVita, a leading US provider of kidney care and dialysis. At DaVita, he had responsibility for business operations that generated approximately 20% of the company’s revenue, which exceeded US$6 billion. Previously, Drake held several positions of increasing responsibility within various healthcare business units at Covidien, over a period of 17 years.
“We are thrilled to welcome Scott to our board of directors, and look forward to his contribution to AtriCure. As a seasoned executive, Scott has significant leadership experience managing growing businesses, achieving sustainable revenue growth and driving operational improvements. I believe he will bring meaningful value to AtriCure and to our board of directors,” said Michael Carrel, president and CEO of AtriCure.
“I am pleased to be joining AtriCure’s board of directors, and look forward to contributing to the company’s ongoing success and commercial efforts,” said Drake. “AtriCure is at an exciting stage in its development as a company, and is emerging as a true leader in the field of atrial fibrillation.”
“Dr Harrison was critical to the founding of AtriCure, and his extensive clinical and scientific expertise in cardiology and knowledge of atrial fibrillation have been invaluable to AtriCure’s success,” said Carrel.
